Pharma BD Deal Intelligence
MediGene paid ~$77M in stock for oncolytic HSV assets it never commercialized, gave up the program in 2010 for equity in a spinoff, and the science only proved out (Imlygic royalties via Amgen, and a real NEJM-validated pediatric glioma result) years later under other owners' control.
Full analysis, sources & comparables →MediGene CEO framed the all-stock transaction as moving the company 'into the league of major international biotech players in oncology,' adding two clinical…
Technology evaluation of NV-1020 (MediGene) — a recombinant oncolytic HSV in clinical development for hepatic metastases of colorectal cancer; assessed as a…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
MediGene AG acquired NeuroVir Therapeutics Inc. in an all-stock transaction valued at approximately $77 million, adding NeuroVir's oncolytic herpes simplex virus (HSV) virotherapy platform — including NV-1020 for hepatic metastases of colorectal cancer — and US clinical-development operations to a portfolio previously concentrated in cardiology and dermatology. The deal closed January 16, 2001.
MediGene paid ~$77M in stock for oncolytic HSV assets it never commercialized, gave up the program in 2010 for equity in a spinoff, and the science only proved out (Imlygic royalties via Amgen, and a real NEJM-validated pediatric glioma result) years later under other owners' control.
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| MediGene AG / NeuroVir Therapeutics Inc. (this deal) | 2001 | $77M | 24 |
| Abbott Laboratories / Knoll Pharmaceutical Company (BASF Pharma) | 2001 | $6.9B | 100 |
| Vertex Pharmaceuticals Incorporated / Aurora Biosciences Corporation | 2001 | $592M | 95 |
| Amgen Inc. / Immunex Corporation | 2001 | $16.0B | 91 |
| Swedish Orphan Biovitrum AB / Biovitrum | 2001 | $493M | 84 |
| Barr Laboratories Inc. / Duramed Pharmaceuticals Inc. | 2001 | $589M | 82 |
| Cephalon Inc. / Group Lafon (France) | 2001 | $450M | 80 |
← Browse all deals · How we score deals
More: 2001 deals